Maxillary sinus augmentation is a fundamental procedure in implant dentistry designed to address deficient vertical bone height in the posterior maxilla. By elevating the sinus membrane and ...
Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release. Propel previously shared a billing code with Intersect ENT’s ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...
Intersect ENT showed it has another device to add to its line of sinus implants, touting positive data from a pilot study of its new steroid delivery implant to treat chronic sinusitis. The ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a ...
Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...
DrBicuspid.com is pleased to present the next column from two lawyers who spend every day defending dentists in litigation and before the licensing board. The purpose of this column is to offer our ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results